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A B S T R A C T
During thyroid surgery, the functional integrity of the recurrent laryngeal nerve (RLN) is not only threatened
by direct nerve injury resulting from accidental transection, clipping or ligation. In fact, indirect trauma, e.g.
traction and compression occurring repeatedly throughout gland dissection, contribute to long-term nerve
impairment. In order to avoidRLN lesions andpreserve nerve function the surgeonmust adhere to and comply
with a strict standardized intraoperative neuromonitoring (IONM) technique to preserve results, quality and
safety.
IONM should be a team work between the surgeon and the anesthesiologist.
© 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
1. Introduction
By conveying both information and emotion in a unique way, the
voice represents the essential part of human communication. 1
Although modern thyroid surgery was inaugurated more than
hundred years ago, recurrent laryngeal nerve (RLN) injury is still
the most dreaded complication. In 1938 Lahey and Hoover ﬁrst
proposed routine identiﬁcation of the RLN during thyroid surgery,
which decreased RLN palsy rates effectively. Today, an overall palsy
rate of approximately 11% remains in routine thyroid surgery; 0.5–2%
in normal goiters and even up to 20% in cancer, Graves’s disease or
in redo-thyroidectomies. 2–6 Since approximately 5–7% of the world
population suffer from thyroid disease, and approximately 10–15%
have to undergo surgery, better RLN protection is clearly needed. 7
In the late 1960s, intraoperative neuromonitoring (IONM) promised
to eliminate RLN injury. 8 While RLN identiﬁcation was improved
by IONM, clinical evaluation showed no signiﬁcant reduction of
the palsy rates. 9–15 New insights into the mechanisms of RLN
injury have revealed striking deﬁciencies of traditional (intermittent)
IONM (I-IONM). RLN functional integrity is not only threatened by
direct nerve injury resulting from accidental transection, clipping
or ligation. In fact, indirect trauma e.g. traction and compression
occurring repeatedly throughout gland dissection contribute to long-
term nerve impairment. 16,17 Literally, “monitoring” implies watching
and checking a condition or parameter over a period of time, allowing
for performing necessary action. 18 I-IONM failed to provide this.
In order to overcome these deﬁciencies, some authors demanded
“continuous” intraoperative neuromonitoring. 19,20 Meanwhile sev-
eral groups presented their ﬁrst results on real-time, continuous
intraoperative neuromonitoring systems (C-IONM). 2–16,16–22 All of
the presented C-IONM systems employ the vagus nerve for placement
of the stimulation electrode. However, potential side effects of
“continuous” vagal nerve stimulation within IONM are virtually
unknown.
There is an increasing interest in IONM and in recent years
numerous Institutions are beginning to perform more monitored
thyroidectomies. 23,24 Attitudes changed with the introduction of
non-invasive monitoring devices, the publication of randomized
prospective trials, guidelines deﬁning standards both for RLN and
superior laryngeal nerve (SLN) monitoring, structured courses and
description of clinical, legal and research implications. 2,25–30
Therefore, it is important to acquaint surgeons with this device,
providing them with an overview of the most important issues
encountered in practice while offering them practical strategies
and tips to improve the safety and quality of IONM performance.
Furthermore, it is essential that the safety of a new procedure be
established before it is widely used on patients.
International guidelines have been published with the intention
to improve the quality and safety of monitoring and to discourage
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inappropriate variations on the IONM technique both for the RLN and
for the superior laryngeal nerve (SLN). 30,31
Indeed, standardization has a fundamental role in increasing the
security and success of a novel technique. 32 In this regard, the
present paper aims to describe the key issues that must be addressed
to ensure a safe introduction of I-IONM and C-IONM into clinical
practice.
The questions that may arise are: What is different between
thyroidectomies with and without IONM? Do these differences
produce any side effects? Do side effects affect routine surgical
practice?
In detail, concerns about IONM safety might arise from the
following issues:
• Anesthesia
• Vagal nerve (VN) dissection and placement of stimulation probe
• Stimulation of the nerves
• Surgeon’s methodology
2. Anesthesia
2.1. Induction and electromyography (EMG) – endotracheal tube
insertion
Different IONM techniques have been proposed, including laryngeal
palpation, glottic pressure monitoring, glottic observation, endo-
scopically placed intramuscular vocal cord electrodes, intramuscular
electrodes, endotracheal tube-based surface electrodes, and post-
cricoid surface electrodes. 30
The system of endotracheal tube-based surface electrodes has
become popular for IONM of RLN in thyroid surgery because of its
essential advantages, including ease of setup and use, noninvasive
nature, and the capacity as a surface electrode to contact larger areas
of the target muscles and summate EMG. 23,24,30
Various authors have suggested to use larger size tubes, to avoid
lubricants on the surface of the tube, or to use neuromuscular
blocking agents, in order to achieve a perfect contact between
the mucosa of the vocal cords (VC) and the surface electrodes,
and to evoke and monitor EMG activity throughout the entire
thyroidectomy. 33–43 Laryngeal injury, and particularly VC lesions
caused by intubation and extubation, are related to some risk factors
such as physical trauma itself from the tube, tube size, movement of
the tube, duration of intubation, cuff pressure and design, and type
of anesthesia. 33–43 The incidence of such damage is high, ranging
from 3% to 73%. 33–43 As for thyroid procedures, one study found the
incidence of VC injuries due to intubation and extubation to be higher
than that of RLN injuries (31% vs. 6%). 36
The use of neuromuscular blocking agents improves outcome
as regards laryngeal injuries: without neuromuscular blockade the
VC damage rate is about 42% as opposed to 8% with neuromuscular
blockade. 33–43 It is important to assess whether there could be
reasons to accept the high risk of VC damage during thyroidectomy
without neuromuscular blockade. Pharmacodynamic studies on the
effect of curare on the voluntary muscles demonstrate that the
respiratory muscles are the least susceptible to its pharmacological
effect. 33–43 While, on the one hand, curare has minor effects on the
respiratory muscles and the effects are short-lived because of the
fast washout due to the wide vascular perfusion of these muscles,
on the other hand it appears clear that the risk of VC damage while
intubating without curare for reasons of neuromonitoring is very
high. 33–43 These conclusions were conﬁrmed by the work of Marush
et al. 41 who evaluated curare’s efﬁcacy for neuromonitoring. They
concluded that laryngeal nerve monitoring is possible even during
curare’s effects, 41 so by using rocuronium or succinylcholine we
can achieve excellent conditions for intubation. Thus, the use of
neuromuscular blocking agents (NMBAs) inmonitored thyroidectomy
is essential to achieve clinically acceptable tracheal intubating
conditions and to prevent laryngeal trauma.
As NMBAs can be a potential cause of false-negative responses
during IONM, 33–43 it has been suggested to use a short-acting NMBA
to allow adequate relaxation and ease of EMG endotracheal tube
insertion during IONM, for instance 1–2mg/kg succinylcholine. 43
However, succinylcholine, being a depolarizing NMBA, is associated
with a variety of adverse effects, such as cardiac dysrhythmia, hyper-
kalemia, and malignant hyperthermia. 43 Consequently, most anes-
thesiologists use nondepolarizing NMBAs for reasons of safety. 33–43
When nondepolarizing NMBAs are used, the NMBA dose and the
time point of nerve stimulation are critical for successful IONM,
although some studies have reported the feasibility of IONM after
administration of a nondepolarizing NMBA during thyroid opera-
tion. 33–43 One study 43 demonstrated that in patients who received
two effective doses (ED) of rocuronium (0.6mg/kg), 30 minutes
after rocuronium injection the correlated twitch of neuromuscular
transmission was <5% and the rate of positive EMG response from
vagal stimulation was only 53%; only at 55 minutes after rocuronium
injection did the rate of positive EMG response reach 100% in these
patients. Furthermore, themean EMG amplitudewasmarkedly lower
from the time point of 30 to 60minutes after rocuronium injection. 43
Therefore, 2 ED of rocuronium used for general anesthesia induction
might cause a false-negative response at the early stage of the
operation. We recommend that 1 ED of rocuronium (0.3mg/kg)
be used as the optimal dose for IONM without the application
of neuromuscular transmission monitoring during thyroid surgery.
Positive and high EMG signals were obtained in all patients at an
early stage of operation and satisfactory intubation conditions were
achieved in most patients. 43
Moreover, after intubation of EMG endotracheal tube, signiﬁcant
change in electrode position may occur as the patient’s neck position
is changed from neutral to extended. Poor contact between the
exposed electrodes and true vocal cords may happen and that can
result in monitor dysfunction. The incidence of monitor dysfunction
has been reported to range from 3.8% to 23%. 33–43 Malpositioning of
the EMG endotracheal tube was found the most common cause of
equipment-related problems in several studies. Lu et al. 38 reported
that six cases (5.6%) of monitor dysfunction among 106 patients were
all caused by the malpositioning of electrodes. Also, Dionigi et al. 44
reported that 15 patients (10%) needed further tube adjustment in-
traoperatively because of nonoptimal contact between endotracheal
surface electrodes and vocal cords. Therefore, routine veriﬁcation of
proper electrode position when the patient is fully positioned should
be a standard procedure to substantially reduce the overall moni-
toring problems encountered intraoperatively. 30,33–43 The presence
of normal baseline and adequate measures of impedance as read on
the monitor (impedance value <5kW; impedance imbalance <1.0 kW)
only imply adequate contact between the recording electrodes and
the body, not necessarily correct positioning of the electrodes. Several
assessments, such as respiratory variation, tap test, depth of EMG tube
insertion and repeat laryngoscopy (direct laryngoscopy or ﬁber-optic
laryngoscopy) have been promoted as tube-position veriﬁcation tests,
but repeat laryngoscopy after patient positioning represents themost
accurate method and takes only a few minutes for tube positional
assessment. 30
2.2. Maintenance of anesthesia
It is of note that combinations of nitrous oxide and halogenated
agents, or a combination of propofol and remifentanil, and in-
travenous narcotics do not affect EMG readings. 30,37 In routine
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clinical practice, most used are combinations of nitrous oxide and
halogenated agents or a combination of propofol and remifen-
tanil. 30,37 The depth of anesthesia from these agents must be
sufﬁcient to avoid any spontaneous activity of the vocal cords. 30,37
This level of anesthesia may be deeper than usually employed
when neuromuscular blockage is used. If baseline EMG activity is
substantially high because the level of anesthesia is too low, it will
be difﬁcult to differentiate spontaneous activity from intentionally
evoked (i.e., stimulated) activity.
According to recent observations by Bacuzzi et al., propofol and
remifentanil provide a rapid onset of anesthesia and rapid recovery,
low incidence of postoperative nausea and vomiting, and can be used
safely in patients susceptibile to malignant hyperthermia and greater
depression of pharyngeal and laryngeal reﬂexes. 37 Thus, this drug
combination may be suggested for proper maintenance of anesthesia
in monitored thyroidectomy.
3. Vagal nerve (VN) dissection and probe placement for
I-IONM and C-IONM
A better understanding of the anatomy of the carotid sheath and
the VN may be useful not only to minimize complications but also
to guarantee an accurate IONM. Recently there have been efforts to
enhance the knowledge of the surgical anatomy of the carotid sheath
and the vagal nerve, and to describe techniques for safe access to the
carotid sheath. 45–47
3.1. Surgical anatomy
Medial location of the common carotid artery (CCA) and anterolateral
or lateral location of the internal jugular vein (IJV) are the most
common conﬁgurations in the carotid sheath. 45–47 Few cases of
medial IJV position are observed. 45–47 Tortuosity, kinking, or coiling
of the extracranial carotid arteries may be observed with advancing
age. 45–47 Neck anatomy can be altered by previous surgery (carotid
stenting, cervical spine surgery, previous lymph node dissection,
etc.).
The location of the VN in relation to the CCA and IJV is classiﬁed
as anterior (A ), posterior (P ), posterior to internal jugular vein (Pj ) or
posterior to the common carotid artery (Pc ). 45–47 Most VN lay in the
posterior region of the carotid sheath in the groove between the two
vessels. The P location of the VN is the most common conﬁguration
observed on either side, followedby the Pc (15%) and Pj (8%) locations.
Less than 5% of cases with A location are observed overall. 45–47
The above description is useful in the intraoperative setting. If the
surgeon does not initially identify the VN, or is not conﬁdent with
carotid sheath dissection as in the case of reoperative surgery, a large
goiter, endoscopic thyroidectomy, or a hostile neck, VN identiﬁcation
may be safely expedited with an increase in probe-stimulation
amplitude to 2–3mA without initial blind dissection of the carotid
sheath. 45–47
3.2. Access to the carotid sheath
Access to the carotid sheath for VN stimulation can be achieved safely
in three different ways 45:
– Anterior (or median) approach, through and between the thyroid
lobe medially and the infrahyoid muscles (strap muscles) laterally
(sternohyoid, sternothyroid, thyrohyoid, and omohyoid). Positive
identiﬁcation of the carotid sheath is favored by gentle retraction
and elevation of the thyroid gland in amedial direction and by using
lateral countertraction on the sternothyroidmuscle. This is themost
frequently used access and is commonly used for benign goiters and
direct/cervical/neck endoscopic thyroidectomy.
– Modiﬁed anterior (or intermedian) approach, in between the ster-
nothyroid muscle (medial) and the sternocleidomastoid muscle
(SCM) (lateral). Identiﬁcation of the carotid sheath is achieved by
medial retraction of the thyroid gland and the sternothyroidmuscle
together and lateral elevation to some extent of the SCM. The
technique is useful in re-do operations, thyroidectomy for cancer,
and central and lateral compartment lymphadenectomies.
– Lateral approach. This access method is commonly used for remote
(from the armpit) endoscopic thyroidectomy. Carotid sheath
identiﬁcation is guaranteed by a posterior approach, lateral and
posterior to the SCM. 45
3.3. Dissection and stimulation of the VN
In order to allow safe dissection and stimulation of VN, different
approaches have been described.
3.3.1. Open technique
Nicely elevate the SCM freeing the muscle from the underlying IJV
and CCA. Free the carotid sheath from any muscle ﬁbers as these
could interfere with the stimulation. VN is identiﬁed in the carotid
sheath at the lower pole of the thyroid gland at a very early stage
of the operation. By sharp dissection, open the carotid sheath. Begin
to sweep fatty and areolar tissue in the carotid sheath. The VN
is exposed by dissecting the carotid sheath from just a 10-mm to
15-mm pouch with dedicated tiny spatulas and debrider-aspirator
(Karl Storz, Endoskope™, Tuttlingen, Germany). Thus, not all of the
carotid sheath is completed and routinely inspected. Options for
dissection and controlling of hemostasis during this stage must
exclude any energy-based devices to prevent thermal injury to theVN.
The VN is routinely stimulated with a current/intensity of 1-mA in
the surgical ﬁeld by the application of a stimulator probe. If VN is
not initially identiﬁed, probe-stimulation amplitude is increased to
2–3mA to expedite VN identiﬁcation in the carotid sheath. Most
stimulators have a 10 cm handle, and a 9 cm-long probe with a
ﬂexible and adaptable tip of 0.5mm. The probe’s design is useful for
endoscopic cervical thyroidectomy: the ﬂexible tip of the stimulating
probe allows good access to neural structures in areas outside the
surgeon’s ﬁeld of view. 45 The probe is insulated to the tip to prevent
current shunting. Stimulation duration is set at 100ms, frequency
at 4Hz, and event threshold at 100mV. The monitor is set with a
stimulation artifact suppressionof 2.1ms. Positive identiﬁcation of VN
is identiﬁed by an audible signal and is also seen as a corresponding
bi-phasic waveform EMG signal of the IONMmonitor (intact function
of RLN). The technique described is useful in both conventional and
endoscopic thyroidectomy and both for intermittent IONM and some
continuous IONM probes (anchor probe). A negative EMG response
following distal VN stimulation should lead to vagus stimulation at
the upper pole of the thyroid lobe. 45 If this signal is positive, a
non-RLN can be assumed and a complete mobilization of the vagus
in these patients is required to identify the origin of the non-RLN. In
detail, on the right side, the absence of an EMG signal at this early
stage is considered suggestive of the presence of a non-recurrent
laryngeal nerve (NRLN). 46 In the presence of a negative signal, the
left vagus nerve must be also be checked to assess the position
of the endotracheal tube, to minimize the possibility of a false-
negative ﬁnding due to tube rotation. When NRLN is suspected,
careful dissection of the vagus nerve is performed, including a check
for signal cranially, close to the carotid bifurcation. When EMG is
reported, dissection is oriented toward the likely location of theNRLN.
Therefore, a check of the branch running to the laryngeal cartilage
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is performed to assess the electric signal. Further conﬁrmation of
NRLN function is highlighted also by using the “laryngeal twitch”
during neurostimulation. If there is a negative EMG response at this
point, other problems, such as a technical defect, the application
of muscle relaxants, or a nerve palsy, might be the reason for this
phenomenon. 45
3.3.2. Closed method
This technique was described in detail by Wu et al. 47 Instead of the
conventional VN stimulationmethod, in which the VN is exposed and
directly stimulated with 1.0mA, a novel method of VN stimulation
without vagus nerve exposure was applied. 45 A ball-tip probe is
simply pressed onto the space between the CCA and IJV. When the
nerve is deeply located, the probe can be pressed with force without
fear of penetration injury to the carotid sheath. In detail, the carotid
sheath was identiﬁed by gentle medical retraction of the thyroid
lobe and laryngotracheal complex and by lateral countertraction on
the sternothyroid muscle and sternocleidomastoid muscle. Without
dissecting the carotid sheath to expose the vagus nerve, the ball-
tip probe (nerve stimulator) is simply pressed and mapped onto the
space between the CCA and IJV with a 3-mA stimulus current. In
some cases of large goiters or re-do surgery, in which the carotid
sheath is not directly visible, the surgeon can feel and palpate the
periodic pulsation of the carotid artery, and the VN stimulation can
be performed by stimulating around the carotid artery that is felt
by the surgeon’s ﬁnger. 45 The results of Wu et al. show that using
a ball-tip nerve stimulator and 3-mA stimulus current for indirect
VN stimulation is not only feasible but also reliable, rendering vagal
stimulation simple and safe during IONM of the RLN. 47
3.3.3. Circumferential 360° VN dissection
To recognize imminent RLN injury, thus avoiding nerve palsy and
to overcome the main obstacle of standard (intermittent) IONM, i.e.,
diagnosis of loss of signal (LOS)whenRLN lesion has already occurred,
C-IONM has been developed in recent years. 16,20–22 Indeed, standard
(intermittent) IONM limits the evaluation of the functional integrity
of the RLN to the short time interval of stimulation and the site of
direct stimulation. C-IONMbeneﬁts from special vagus electrodes and
provides continuous “on-line” information on changes of amplitude
and latency during dissection. C-IONM is able to test the integrity
of the RLN during dissection, allows permanent evaluation of the
RLN, and thus might perceive imminent RLN stress, risk, danger, and
failure. Surgical maneuvers can be correlated to nerve function by
synchronization of anatomy and function of the preoperative intact
RLN. 16,20–22 Theoretically, in case of a weakening EMG signal the
surgeon reacts early intraoperatively to the RLN stress/risk/danger/
injury/failure and RLN injury becomes reversible. 16,20–22 Several
C-IONM probes are available commercially, with differences in
design, geometry, size, adaptability, versatility, hindrance and mode
of stimulation (bipolar vs. monopolar). 16,20–22 The most common
C-IONM probes have a closed design and geometry. This is essential
to prevent any dislocation of the C-IONM probes and for an EMG
signal that has stable amplitude and latency. 16,20–22 Therefore, they
must surround the VN completely. Thus, a circumferential dissection
of the VN is required: for optimal placement, the vagus nerve is
dissected 360° at the carotid sheath by means of an approximately
15-20-mm pouch and subsequent gently positioning of the C-IONM
probe. We suggest to avoid dissecting arterial and venous blood
supply of the nerve while preparing its course. Keep the surgical
ﬁeld dry with a swab to avoid any artifacts and/or signal shunting.
The authors agree that, ideally, C-IONM probes should be available in
different sizes and optimized for different situations and distributions
of theVN. In fact, VNpositionmaydiffer betweenpatients and the size
may increase during the surgical procedure for local edema. 16,20–22 If
the surgeon doing the implantation has different sizes and adaptable
C-IONM electrodes available in the operating room, then the most
appropriate one for the patient can be selected at the time of
implantation. Finally, visually inspect the C-IONM electrode to ensure
that it is completely attached around the nerve, without pinching the
nerve.
4. Stimulation of the nerves
In general, issues regarding safety of stimulation might be perceived
to concern:
a. Direct trauma to the nerve by the stimulator itself.
b. Stimulation-induced tissue trauma due to
– Intensity level (tissue is over-stimulated),
– Stimulation rate (greater than physiologically tolerated),
– Duration of the stimulation (fatigability).
c. Stimulation inpediatric patients andpatientswith co-morbidities.
d. Systemic effects of VN stimulation (VNS).
For items (a)–(c), there is robust evidence from the literature that
stimulation is safe. 48 Therefore we will analyze only item (d) in
detail.
4.1. Potential side effects of C-IONM via VNS
The relatively new technology of C-IONMviaVNS is increasingly being
applied in thyroid surgery. The required nerve stimulation and EMG
recording technology has been approved according to international
standards, but clinical side effects of continuous vagal nerve stimu-
lation must be deduced from therapeutic VNS, even though different
stimulation parameters are used in C-IONM. Generally, implantation
and application of therapeutic VNS systems is considered safe,
resulting in negligible mortality and low morbidity. The vagal nerve
as a mixed cranial nerve comprises mostly parasympathetic ﬁbers
(20% afferents and 80% efferents). 49 Therapeutic VNS for epilepsy
and depression relies on afferent stimulation. Typically, two helical
bipolar platinum electrodes are wrapped around the left vagus
nerve distal to the superior laryngeal nerve and superior and
inferior cervical cardiac branches. The generator typically provides
0.5-ms pulses at 10–30 pulses per second (pps) for 30 seconds,
every 2–4minutes. 50 The current output is increased by 0.25–0.5mA
every 2–4 weeks until the optimum current output for stimulation
is obtained. 51 Except for the stimulation rate and duration, the
stimulation parameters in C-IONM are comparable.
The majority of reported side effects of VNS are temporary. They
include voice alterations, dysphagia, altered breathing patterns and
pain. As long as C-IONM is applied under general anesthesia during
thyroid surgery, these side effects are clinically irrelevant. However,
there have also been reports of cardiac arrhythmias or hemodynamic
alterations that need to be considered in assessing the safety of
C-IONM. 52–54 These events have been reported only rarely, and were
attributed to increased parasympathetic activity.
We have performed a preliminary study to determine if heart rate
variability analysis (HRVA) could be a suitable tool for measuring
autonomous nervous system (ANS) activity and parasympathetic vs.
sympathetic balance during C-IONM. Heart rate variability analysis
proved to be suitable for identifying and quantifying cardiac effects.
In the study, a unique parasympathetic alignment of ANS activity
was observed. 55 The following results were obtained using a
tripolar stimulation electrode, a supramaximal stimulation current
of 0.5–5mA, stimulation rate of 2–3pps and a pulse width of 200ms.
In a series of 40 patients comparing HRVA in C-IONM vs. I-IONM we
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demonstrated a reduction of overall ANS activity with induction of
general anesthesia in both groups (I-IONM vs. C-IONM). Throughout
the observed interval comprising VNS, ANS activity showed only
little ﬂuctuation. Also, both groups seemed to show the same
course of ANS activity. However, detailed analysis revealed signiﬁcant
differences. 56
4.1.1. Dynamics of the onset of ANS effects during VNS
Most cardiac complications from therapeutic VNS were reported at
the onset of stimulation. 57,58 In our study, HRVA accordingly revealed
a remarkably prompt and strong shift of the ANS balance toward vagal
tone at the onset of VNS; for several minutes, only vagal activity could
be detected, and no sympathetic response was noted. 59 This missing
counteraction could be one reasonwhy arrhythmia often occurs at the
onset of VNS.
4.1.2. Persistence of the ANS effect during VNS
Although pre- and postoperative parasympathetic activity showed
high concordance in both groups, parasympathetic activity consis-
tently decreased during VNS for patients of the I-IONM group while
it remained consistently high in the C-IONM group. After cessation of
VNS, elevated parasympathetic activity was still recorded, resulting
in signiﬁcantly higher vagal tone than in individuals who had not
received VNS during thyroid gland preparation. 60
4.1.3. What inﬂuences ANS effects during VNS?
As mentioned above, the stimulation parameters for therapeutic
VNS are almost the same as those for C-IONM. However, the
stimulation rate is considerable higher in therapeutic VNS, and the
stimulation current is incrementally increased by up to 0.5mA at a
time for weeks. Three case series 61–63 have shown that vagus nerve
stimulation has the potential to change respiratory patterns during
both wakefulness and sleep; in addition, dyspnea and voice changes
occurred during VNS. There is evidence hinting that these changes or
alterations depend on the stimulation rate, with higher stimulation
rates resulting in more signiﬁcant dyspnea and voice changes. 64
Therefore, we analyzed our C-IONM data with different currents and
conducted an animal study testing different stimulation currents and
rates.
In C-IONM patients we saw no signiﬁcant correlation between
stimulation current and elevated vagal nerve activity. The in-vivo
experiments revealed that only stimulation currents above 10mA led
to a general increase of ANS activity. Interestingly, the stimulation rate
has a reproducible and signiﬁcant inﬂuence on heart rate. An increase
in heart rate was observed upon stimulation rates above 10pps. This
was accompanied by an increased ANS activity, though mostly in the
very-low-frequency domain (VLF). The physiological relevance of VLF
is not well understood up to date. Our data suggest that stimulation
currents beyond 10mA and stimulation frequencies beyond 10Hz
provoke a systemic stress reaction, which could impact the safety of
C-IONM.
4.2. Effects on the immune system
The immunomodulatory effects of VNS are potentially relevant for
surgical patients, as the anti-inﬂammatory impact attributed to
VNS might counteract regular wound healing. 65–69 Until now, no
damage to the vagal nerve itself due to the demanding preparation
of the vagal nerve has been reported for I-IONM or C-IONM. In
carotic endartectomy, however, cranial and peripheral nerve injury
is a common complication, occurring in 3–23%. 70 Two randomized
controlled trials demonstrated that 8.6% and 6.3% of patients,
respectively, had at least one peripheral nerve injury. 71 Most of these
injuries were temporary, but a potential risk for paralysis remains.
In addition to its inﬂuence on hemodynamics, VNS-induced
parasympathetic predominance has been associated with strong im-
munomodulatory effects. 65,72–74 Cytokine release of TNF-a especially
appears to be highly susceptible to VNS. 74,75 However, proinﬂam-
matory cytokines are crucial in postoperative wound healing. 68,69
Consequently, we analyzed serum concentrations of TNF-abefore,
during, and after the observation interval. Even though described
in the literature, no attenuation of TNF-arelease was detected in
our study. Baseline values provided from every patient prior to
surgery further validated the results of cytokine analysis. Blood
samples obtained from septic patients in the intensive care unit
at our institution were used as internal controls and demonstrated
greatly elevated TNF-aserum levels. One could argue that relatively
subtle, sterile, surgical trauma as in thyroid and parathyroid surgery
does not induce a signiﬁcant inﬂammatory response, and therefore
no immunosuppressive effect of VNS could be identiﬁed. Therefore, in
further studies additional analysis of high-mobility group protein B-1
(HMGB-1) could be valuable, as HMGB-1 levels are described to be
strongly increased upon cell damage.
4.3. Effects on the lung and the upper intestine
Because of the fact that VNS for C-IONMwas used only under general
anesthesia, dyspnea or effects on respiratory pattern were negligible.
Nausea and vomiting is another well-known side effect of therapeutic
VNS, occurring in 2–20%.We did not observe post-operative nausea or
vomiting related to C-IONM.
5. Surgeon’s methodology
An adverse event is an undesired effect resulting from a new
procedure. Such event may be related to the technology itself (i.e.
malfunction) or to the surgeon. Indeed, the surgeon may cause un-
intended consequences due to inappropriate technique, incomplete
learning curve, not using standardized methodology, low experience,
and wanting behavior in acquiring and correctly integrating the new
procedure.
Strict standardization is usefulness tomaintain standards, to obtain
better outcomes of surgical treatment, to verify safety of new
technology, for technical training and surgical education, and for
ratiﬁcation, repeatability and interoperability.
The standardization of IONM was ﬁrst proposed and applied by
Chiang 8,30 and subsequently improved; it involves several discrete
moments:
• Structured informed consent (discuss the possibility of staging
thyroidectomy)
• L1 : preoperative laryngoscopy
• V1 : stimulation of the VN before dissection
• R1 : stimulation of the RLN at ﬁrst identiﬁcation
• R2 : stimulation of the RLN after complete hemostasis
• V2 : stimulation of the VN at complete hemostasis
• L2 : postoperative laryngoscopy
• Printed EMG documentation
If a standardized procedure is followed attentively, it supports
any intraoperative surgical deliberations (such as the decision to
stage thyroidectomy), it assists in modiﬁcation of surgical technique
(reﬁnement) and consolidates the correct evaluation of the results
(improvement). The surgeon must adhere to and comply with a
strict standardized IONM technique to preserve results, quality and
safety; appropriate stimulation protocols must be veriﬁed. High-
quality IONM is fundamental for making any surgical deliberation, for
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safety and to reduce false positive results. The role of the surgeon is
critical to have excellent quality of IONM.
An unequivocal deﬁnition of normative EMG data is mandatory.
The surgeon together with the anesthesiologist should optimize
EMG signal, and in particular the V1 signal, by means of appropriate
veriﬁcation of electrode materials and stimulation protocols, correct
EMG tube position and proper use of induction and maintenance
anesthesia drugs.Members of the IONMStudy Group have proposed a
proper deﬁnition/level for V1 amplitude of >500mV. 30 The V1 signal
is the prerequisite for the correct interpretation, diagnosis and
veriﬁcation of a functional intact RLN, for deﬁnition of a “signiﬁcant”
reduction of signal, “re-entry” signal, loss of signal (LOS) and again for
the correct evaluation of the results.
6. Conclusion
The surgeon must adhere to and comply with a strict standardized
IONM technique to preserve results, quality and safety.
IONM should be teamwork between the surgeon and the anes-
thesiologist. Veriﬁcation of proper positioning of the electrodes
and carefully delivering NMBAs during EMG endotracheal tube
insertion are the key to safe IONM. According to a recent survey
on most common agents used for induction and maintenance
of anesthesia, NMBAs and propofol/remifentanil were used most
frequently (80–96%) in routine clinical practice. 30 Therefore there
are no substantial changes in the clinical practice with respect
to anesthesia, both induction and maintenance. Hence, there are
some advantages for the anesthesiologist in using IONM: (a) IONM
indicates periods of light anesthesia, (b) IONM eliminates the need
for visual assessment of VC function at the time of extubation and
(c) IONM indicates the potential for bilateral vocal cord paralysis.
Appropriate stimulation protocols must always be veriﬁed before
andduring the surgical procedure. I-IONM is a safe procedure. There is
a consensus about the fact that 1mA stimulation intensity amplitude
is safe. 30 Supramaximal stimulationwith 2–3mAshould be used only
to localize the RLN and/or the VN. The safety of VN stimulation has
been demonstrated for IONM of the thyroid, parapharyngeal space
operations, and treatment for intractable epilepsy. 30
We have to emphasize that C-IONM should only be used by
surgeonswho arewell trained or have ample experiencewith I-IONM.
C-IONM via VNS with the regular parameters is safe; a distinct effect
on parasympathetic activity is seen, but that seems to have no effect
on heart rate, blood pressure and the other systems afﬁliatedwith the
vagus nerve. Nevertheless, relevant effects could appear when using
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